Table 1:
Anti-LILRB3 inhibits the activity of MDSCs from some patients with cancer.
| Human cancer type | MDSC/T co-culture | MDSC culture | ||||
|---|---|---|---|---|---|---|
| No. of cases |
anti-LILRB3 efficacya |
% efficacy |
No. of cases |
anti-LILRB3 efficacyb |
% efficacy |
|
| Prostate cancer | 24 | 8 | 33 | N.A. | N.A. | N.A. |
| Melanoma | 41 | 18 | 44 | 30 | 4 | 13 |
| Lung cancer | 10 | 4 | 40 | 7 | 2 | 29 |
| Breast cancer | 1 | 1 | 100 | N.A. | N.A. | N.A. |
| Total Cases | 76 | 31 | 41 | 37 | 6 | 16 |
a
Increased T cell proliferation with anti-LILRB3 treatment.
b
Increased CD86 and decreased CD163 and CD206 with anti-LILRB3 treatment.